INE963
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Malaria: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| INE963: this drug | Stage not on record | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ganaplacide / Lumefantrine | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Cipargamin | Phase 2 | Small molecule | PfATP4 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK3772701 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4024484 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4425689 | —(overall) | Undisclosed | Circumsporozoite protein (CSP) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.